1. Home
  2. DMRC vs ENTX Comparison

DMRC vs ENTX Comparison

Compare DMRC & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Digimarc Corporation

DMRC

Digimarc Corporation

HOLD

Current Price

$5.61

Market Cap

183.5M

Sector

Technology

ML Signal

HOLD

Logo Entera Bio Ltd.

ENTX

Entera Bio Ltd.

N/A

Current Price

$3.00

Market Cap

147.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DMRC
ENTX
Founded
2008
2010
Country
United States
Israel
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
183.5M
147.4M
IPO Year
2026
2015

Fundamental Metrics

Financial Performance
Metric
DMRC
ENTX
Price
$5.61
$3.00
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$10.00
$9.00
AVG Volume (30 Days)
108.2K
335.2K
Earning Date
05-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.22
Revenue
N/A
$42,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$13.27
Revenue Growth
N/A
N/A
52 Week Low
$4.07
$0.91
52 Week High
$17.47
$4.20

Technical Indicators

Market Signals
Indicator
DMRC
ENTX
Relative Strength Index (RSI) 39.89 50.66
Support Level $5.57 $2.66
Resistance Level $7.10 $3.10
Average True Range (ATR) 0.55 0.23
MACD -0.07 -0.07
Stochastic Oscillator 22.49 13.17

Price Performance

Historical Comparison
DMRC
ENTX

About DMRC Digimarc Corporation

Digimarc Corp is a product digitization company delivering business value across industries through identities and cloud-based solutions. Its solutions are Anti-counterfeiting, Internal Compliance, Leak Detection, Piracy Prevention, Product Swap Prevention, Provenance & Authenticity (C2PA), Recycling, and Royalty Monitoring. The group offers services to various industries such as Consumer Packaged Goods, Government, Media, Pharmaceutical, and Retail.

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.

Share on Social Networks: